Keytruda (pembrolizumab) — J9271

Keytruda IV vs. Keytruda Qlex

Keytruda (pembrolizumab) received FDA approval in September 2014. The IV formulation (J9271) has billed under that code since it took effect January 1, 2016, replacing the temporary C9027 code; Keytruda Qlex (J9277) is the subcutaneous version, approved September 19, 2025, under a separate BLA with its own NDCs and admin code.

Keytruda Qlex is a fixed dose — 395 mg every 3 weeks or 790 mg every 6 weeks, no weight-based option — given subcutaneously in 1–2 minutes under CPT 96401. Keytruda IV's infusion runs 30 minutes and bills 96413. J9277 has no ASP history before Q2 2026.

Keytruda dosing

Adult dosing is flat, not weight-based — the choice is the schedule, not the mg/kg.

Most indications cap treatment at 24 months without progression; adjuvant regimens have their own limits. Combination regimens (NSCLC + chemo, RCC + axitinib or lenvatinib, HER2+ gastric + trastuzumab, urothelial + Padcev, ovarian + paclitaxel ± bevacizumab) use the same 200 mg q3w dose alongside the combination agent. No premedication is required.

Convert dose to J9271 billing units →

Keytruda billing reference

HCPCS

J9271 bills 1 mg per unit — not 1 vial, not 10 mg like some biologics. A 200 mg dose is 200 units.

NDCs

Use the carton-level NDC, not the vial-level NDC — payers expect the carton NDC on the claim form.

Administration

CPT bills pembrolizumab as chemotherapy administration, not immunotherapy administration — monoclonal antibodies get the chemo admin codes regardless of mechanism.

CPT's chemotherapy administration range (96409–96425) applies to complex drug and biologic administration by injection or infusion technique regardless of mechanism of action — it's why an immune checkpoint inhibitor like pembrolizumab bills under chemo admin codes instead of the therapeutic-infusion codes (96365/96366).

Modifiers

JZ — required when no drug is discarded. JW — required for documented waste of unused single-dose-vial drug.

CMS requires JZ on every single-dose-container claim with no waste, effective July 1, 2023. The 200 mg dose draws two 100 mg vials with zero waste; the 400 mg dose draws four — JZ is the norm on almost every adult claim.

JW arises only with the pediatric weight-based dose (2 mg/kg, up to 200 mg). Example: a 25 kg child receiving 50 mg uses one 100 mg vial and discards 50 mg — bill the administered units on one line (no wastage modifier) and JW with 50 units of waste on a separate line, same date of service. One of JZ or JW must be on every J9271 claim.

Add modifier 25 to the same-day E/M code when you perform a significant, separately identifiable evaluation and management service on the date of the infusion. Routine pre-infusion assessment is bundled into the administration code and doesn't qualify on its own.

For 340B-acquired units, append modifier TB. CMS discontinued JG for all 340B-covered entities on January 1, 2025 (MLN4800856), leaving TB as the sole 340B identifier, so a claim carrying JG today is using a retired modifier. Merck’s billing guide gives no product-specific 340B instructions beyond that.

Claim form

CMS-1500 / 837P field map for a J9271 claim.

Calculate units, vials & JW/JZ →

Keytruda coverage & access

CareCost's payer-policy library doesn't cover immuno-oncology yet. Use the Medicare diagnosis table below, and the payer's own policy, for a live PA.

• Aetna CPB 0892 moves immune checkpoint inhibitors out of hospital outpatient after the first 3 months, unless the patient is on combo chemo or being managed for toxicity.
• MSI-H/dMMR and TMB-H (≥10 mut/Mb, FoundationOne CDx) results are required for tissue-agnostic and CRC indications — ICD-10 alone doesn't get the PA approved.

ICD-10-CM by indication

21+ approved indications. Use the most specific code supported by encounter documentation.

Full FDA-indicated ICD-10 reference: Medicare covered diagnoses for Keytruda →

Biomarker test billing

Bill the biomarker test on its own claim line — it's separate from the J9271 drug claim.

Keytruda's label doesn't name one test — it requires selection “as determined by an FDA-authorized test” and points to FDA's companion-diagnostic list for which one qualifies. For pembrolizumab that's PD-L1 IHC 22C3 pharmDx. Nivolumab (Opdivo) pairs with a different clone, 28-8 pharmDx; atezolizumab (Tecentriq) with VENTANA SP142.

TPS, CPS and IC scores are different measurements on different antibody clones, so a PD-L1 result from another agent's workup doesn't automatically satisfy a Keytruda PA. Confirm the pathology report names both the clone and the scoring system before you submit, and budget for a re-stain on 22C3 if it doesn't.

Step therapy

Not required for FDA-labeled first-line indications. Some payers require documented prior platinum-chemotherapy failure before pembrolizumab monotherapy in second-line-plus settings — post-platinum urothelial and NSCLC with PD-L1 TPS under 1%, for example. Verify the specific payer's policy before assuming step therapy applies.

Keytruda pricing

Medicare ASP+6%: $60.645 / 1 mg · $12,129.00 / 200 mg. The 2% sequester cut reduces Medicare's 80% share (effective ASP+4.3% overall).

17 doses a year (200 mg q3w) at $12,262.27 per infusion — drug plus 96413 administration — total $208,458.59 before the sequester. Commercial plans pay a contracted rate that varies by payer and state.

Look up commercial reimbursement →

Cost & reimbursement

Patient responsibility = payer allowed rate − benefits adjustment − assistance. Because a single dose exceeds $12,000, the Part B deductible and a Medigap plan swing this by thousands of dollars.

Calculate a Keytruda patient estimate →

Copay & financial assistance

Commercial: the Merck Co-pay Assistance Program pays after the first $25 per administration, up to $25,000 per patient per 12 months — commercial insurance only; the administration charge itself is not covered. Uninsured: the Merck Patient Assistance Program provides free product for patients meeting income requirements. Medicare: oncology foundation funds (HealthWell, PAN, The Assistance Fund, Good Days) offer diagnosis-specific awards by cancer type — check current open/closed status before assuming availability.

See current Keytruda assistance programs →

Common Keytruda denials & fixes